Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy
dc.contributor.author | Lowe, Nick J. | en_US |
dc.contributor.author | Gonzalez, John | en_US |
dc.contributor.author | Bagel, Jerry | en_US |
dc.contributor.author | Caro, Ivor | en_US |
dc.contributor.author | Ellis, Charles N. | en_US |
dc.contributor.author | Menter, Alan | en_US |
dc.date.accessioned | 2010-04-01T15:21:02Z | |
dc.date.available | 2010-04-01T15:21:02Z | |
dc.date.issued | 2003-03 | en_US |
dc.identifier.citation | Lowe, Nick J.; Gonzalez, John; Bagel, Jerry; Caro, Ivor; Ellis, Charles N.; Menter, Alan (2003). "Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy." International Journal of Dermatology 42(3): 224-230. <http://hdl.handle.net/2027.42/65825> | en_US |
dc.identifier.issn | 0011-9059 | en_US |
dc.identifier.issn | 1365-4632 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/65825 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=12653922&dopt=citation | en_US |
dc.description.abstract | Background Psoriasis is a chronic, relapsing skin disease that may require multiple treatment courses. Alefacept targets the memory T cells implicated in psoriasis pathogenesis. This open-label study evaluated the safety and tolerability, efficacy, and pharmacodynamics of repeat courses of alefacept in men and women with chronic plaque psoriasis. This article reports the interim results of this ongoing study. Methods Patients ( n = 174) who participated in previous phase II studies of alefacept were included in this retreatment study. Intravenous alefacept (7.5 mg) was administered once weekly for 12 weeks followed by 12 weeks of observation. Initial and subsequent retreatment courses were only given when, in the opinion of the investigators, disease had returned and necessitated treatment; CD4 + T-cell counts had to be at or above the lower limit of normal. Results Adverse events were similar regardless of the retreatment course. No opportunistic infections, rebound of disease, or flares were reported. Low titers of anti-alefacept antibodies occurred in a few patients without related safety issues. Sixty-six per cent of patients achieved a ≥ 50% reduction in the Psoriasis Area and Severity Index (PASI) at any time after the first dose of retreatment course 1. Patients who received two retreatment courses ( n = 50) had consistent or improved responses after the second course; 64% and 68% of these patients achieved a ≥ 50% PASI improvement at any time after the first dose of retreatment courses 1 and 2, respectively. Alefacept selectively reduced memory T cells without cumulative effects. Conclusions Repeat courses of alefacept were well tolerated, and subsequent retreatment courses were at least as effective as the initial course of therapy. | en_US |
dc.format.extent | 222851 bytes | |
dc.format.extent | 3110 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Science Ltd | en_US |
dc.rights | © 2003 The International Society of Dermatology | en_US |
dc.title | Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Dermatology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | From Clinical Research Specialists, Santa Monica, California, Sylvana Research, San Antonio, Texas, Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, University of Michigan Medical School, Ann Arbor, Michigan, and Baylor University Medical Center, Dallas, Texas | en_US |
dc.identifier.pmid | 12653922 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/65825/1/j.1365-4362.2003.01793.x.pdf | |
dc.identifier.doi | 10.1046/j.1365-4362.2003.01793.x | en_US |
dc.identifier.source | International Journal of Dermatology | en_US |
dc.identifier.citedreference | Christophers E. Psoriasis – epidemiology and clinical spectrum. Clin Exp Dermatol 2001 ; 26 : 314 – 320. | en_US |
dc.identifier.citedreference | Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996 ; 14 : 485 – 496. | en_US |
dc.identifier.citedreference | 3 National Psoriasis Foundation. About psoriasis. Available at http://www.psoriasis.org. Accessed April 2002. | en_US |
dc.identifier.citedreference | Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001 ; 137 : 280 – 284. | en_US |
dc.identifier.citedreference | Barker JN. Psoriasis as a T cell-mediated autoimmune disease. Hosp Med 1998 ; 59 : 530 – 533. | en_US |
dc.identifier.citedreference | Robert C, Kupper TS. Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med 1999 ; 341 : 1817 – 1828. | en_US |
dc.identifier.citedreference | Miller GT, Hochman PS, Meier W, et al. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med 1993 ; 178 : 211 – 222. | en_US |
dc.identifier.citedreference | Majeau GR, Meier W, Jimmo B, et al. Mechanism of lymphocyte function-associated molecule 3–Ig fusion proteins inhibition of T cell responses: structure/function analysis in vitro and in human CD2 transgenic mice. J Immunol 1994 ; 152 : 2753 – 2767. | en_US |
dc.identifier.citedreference | Sanders ME, Makgoba MW, Sharrow SO, et al. Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-γ production. J Immunol 1988 ; 140 : 1401 – 1407. | en_US |
dc.identifier.citedreference | Majeau GR, Whitty A, Yim K, et al. Low affinity binding of an LFA-3/IgG1 fusion protein to CD2 + T cells is independent of cell activation. Cell Adhes Commun 1999 ; 7 : 267 – 279. | en_US |
dc.identifier.citedreference | Ellis CN, Krueger GG for the Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001 ; 345 : 248 – 255. | en_US |
dc.identifier.citedreference | Fredriksson T, Pettersson U. Severe psoriasis – oral therapy with a new retinoid. Dermatologica 1978 ; 157 : 238 – 244. | en_US |
dc.identifier.citedreference | Lim KK, Su WP, Schroeter AL, et al. Cyclosporine in the treatment of dermatologic disease: an update. Mayo Clin Proc 1996 ; 71 : 1182 – 1191. | en_US |
dc.identifier.citedreference | Boffa MJ, Chalmers RJ. Methotrexate for psoriasis. Clin Exp Dermatol 1996 ; 21 : 399 – 408. | en_US |
dc.identifier.citedreference | Lebwohl M, Ali S. Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol 2001 ; 45 : 649 – 661. | en_US |
dc.identifier.citedreference | DiGiovanna JJ. Systemic retinoid therapy. Dermatol Clin 2001 ; 19 : 161 – 167. | en_US |
dc.identifier.citedreference | Stern RS, Liebman EJ, VÄkevÄ L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. J Natl Cancer Inst 1998 ; 90 : 1278 – 1284. | en_US |
dc.identifier.citedreference | Stern RS. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001 ; 44 : 755 – 761. | en_US |
dc.identifier.citedreference | 19 American Cancer Society. Cancer Facts and Figures 2002. Atlanta, GA : American Cancer Society, 2002. | en_US |
dc.identifier.citedreference | Spuls PI, Witkamp L, Bossuyt PM, Bos JD. A systematic review of five systemic treatments for severe psoriasis. Br J Dermatol 1997 ; 137 : 943 – 949. | en_US |
dc.identifier.citedreference | Koo J, Lebwohl M. Duration of remission of psoriasis therapies. J Am Acad Dermatol 1999 ; 41 : 51 – 59. | en_US |
dc.identifier.citedreference | Menter A, Cram DL. The Goeckerman regimen in two psoriasis day care centers. J Am Acad Dermatol 1983 ; 9 : 59 – 65. | en_US |
dc.identifier.citedreference | Haynes BF, Markert ML, Sempowski GD, et al. The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection. Annu Rev Immunol 2000 ; 18 : 529 – 560. | en_US |
dc.identifier.citedreference | Fuhlbrigge RC, Kieffer JD, Armerding D, Kupper TS. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature 1997 ; 389 : 978 – 981. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.